Top

Published in:

Open Access 01-06-2012 | Review Article

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody

Authors: Abhijit Chakraborty, PhD, Stacey Tannenbaum, Christiane Rordorf, Philip J. Lowe, David Floch, Hermann Gram, Sandip Roy

Published in: Clinical Pharmacokinetics | Issue 6/2012

Abstract

Canakinumab is a high-affinity human monoclonal anti-interleukin-1β (IL-1β) antibody of the IgG1/κ isotype designed to bind and neutralize the activity of human IL-1β, a pro-inflammatory cytokine. Canakinumab is currently being investigated on the premise that it would exert anti-inflammatory effects on a broad spectrum of diseases, driven by IL-1β. This paper focuses on the analysis of the pharmacokinetic and pharmacodynamic data from the canakinumab clinical development programme, describing results from the recently approved indication for the treatment of cryopyrin-associated periodic syndromes (CAPS) under the trade name ILARIS®, as well as diseases such as rheumatoid arthritis, asthma and psoriasis.

Canakinumab displays pharmacokinetic properties typical of an IgG1 antibody. In a CAPS patient weighing 70 kg, slow serum clearance (0.174 L/day) was observed with a low total volume of distribution at steady state (6.0 L), resulting in a long elimination half-life of 26 days. The subcutaneous absolute bioavailability was high (70%). Canakinumab displays linear pharmacokinetics, with a dose-proportional increase in exposure and no evidence of accelerated clearance or time-dependent changes in pharmacokinetics following repeated administration was observed. The pharmacokinetics of canakinumab in various diseases (e.g. CAPS, rheumatoid arthritis, psoriasis or asthma) are comparable to those in healthy individuals. No sex- or age-related pharmacokinetic differences were observed after correction for body weight.

An increase in total IL-1β was observed in both healthy subjects and all patient populations following canakinumab dosing, reflecting the ability of canakinumab to bind circulating IL-1β. The kinetics of total IL-1β along with the pharmacokinetics of canakinumab were characterized by a population-based pharmacokinetic-binding model, where the apparent in vivo dissociation constant, signifying binding affinity of canakinumab to circulating IL-1β, was estimated at 1.07 ± 0.173 nmol/L in CAPS patients.

During development of canakinumab a cell line change was introduced. Pharmacokinetic characterization was performed in both animals and humans to assure that this manufacturing change did not affect the pharmacokinetic/pharmacodynamic properties of canakinumab.

Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1 beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20: 319–25PubMedCrossRef

Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46: 3340–8PubMedCrossRef

Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by inter-leukin-1 receptor antagonist. Lancet 2004; 364: 1779–85PubMedCrossRef

Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479–86PubMedCrossRef

Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196–204PubMedCrossRef

So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9: R28PubMedCrossRef

de Kluijver J, Grunberg K, Pons D, et al. Interleukin-1beta and interleukin-1ra levels in nasal lavages during experimental rhinovirus infection in asthmatic and non-asthmatic subjects. Clin Exp Allergy 2003; 33: 1415–8PubMedCrossRef

Rupp J, Kothe H, Mueller A, et al. Imbalanced secretion of IL-1beta and IL-1RA in Chlamydia pneumoniae-infected mononuclear cells from COPD patients. Eur Respir J 2003; 22: 274–9PubMedCrossRef

Debets R, Hegmans JP, Troost RJ, et al. Enhanced production of biologically active interleukin-1 alpha and interleukin-1 beta by psoriatic epidermal cells ex vivo: evidence of increased cytosolic interleukin-1 beta levels and facilitated interleukin-1 release. Eur J Immunol 1995; 25: 1624–30PubMedCrossRef

10.

Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517–26PubMedCrossRef

11.

Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416–25PubMedCrossRef

12.

Bonner J, Lloyd P, Lowe P, et al. PK/PD, safety and tolerability of a human anti-IL-1B monoclonal antibody (ACZ885) in healthy subjects [abstract no. 748]. Annual Congress of the European Respiratory Society; 2006 Sep 2–6; Munich

13.

Novartis. Safety, tolerability, pharmacokinetics and pharmacodynamics of ACZ885 in healthy Japanese male volunteers [ClinicalTrials.gov identifier NCT00421226]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 2]

14.

Alten R, Gram H, Joosten LA, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10: R67PubMedCrossRef

15.

A4 week treatment study to evaluate the safety, tolerability, immunogenicity of single and multiple 150 mg subcutaneous administration of ACZ885 in psoriasis patients [EudraCT identifier 2005-004119-31] European Clinical Trial Database, EudraCT [online]. Available from URL: https://eudract.ema.europa.eu [Accessed on 2012 Apr 3]

16.

Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009; 206: 1029–36PubMedCrossRef

17.

Vugmeyster Y, Tian X, Szklut P, et al. Pharmacokinetic and pharmacodynamic modeling of a humanized anti-IL-13 antibody in naive and ascaris-challenged cynomolgus monkeys. Pharma Res 2009; 26: 306–15CrossRef

18.

Barnes ListItem, Bentley CM, Dickson AJ. Advances in animal cell recombinant protein production: GS-NS0 expression system. Cytotechnology 2000; 32: 109–23PubMedCrossRef

19.

Shulman M, Wilde CD, Kohler G. A better cell line for making hybridomas secreting specific antibodies. Nature 1978; 276: 269–70PubMedCrossRef

20.

European Medicines Agency. Ilaris: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu [Accessed 2012 Apr 2]

21.

FDA label information. Ilaris (canakinumab) [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125319s000lbl.pdf [Accessed 2011 Dec 1]

22.

Mire-Sluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004; 289: 1–16PubMedCrossRef

23.

Boon L, Brok HP, Bauer J, et al. Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses. J Immunol 2001; 167: 2942–9PubMed

24.

Beal SL, Sheiner LB, Boeckmann AJ, et al. NONMEM users guide. Ellicott City (MD): Icon Development Solutions, 2009

25.

Hayashi N, Tsukamoto Y, Sallas WM, et al. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2006; 63: 548–61PubMedCrossRef

26.

Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84: 548–58PubMedCrossRef

27.

Mould DR, Sweeney KRD. The pharmacokinetics and pharmacodynamics of monoclonal antibodies: mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 2007; 10: 84–96PubMed

28.

Kopp WC, Urba WJ, Rager HC, et al. Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer. Clin Cancer Res 1996; 2: 501–6PubMed

29.

Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49: 633–59PubMedCrossRef

30.

West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws for biology. Science 1997; 276: 122–6PubMedCrossRef

31.

West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999; 284: 1677–9PubMedCrossRef

32.

Bouwmeester HJ, Anderson BJ, Tibboel D, et al. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesthesia 2004; 92: 208–17CrossRef

33.

Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 2007; 35: 1687–93PubMedCrossRef

34.

Sunman JA, Hawke RL, LeCluyse EL, et al. Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos 2004; 32: 359–63PubMedCrossRef

35.

Chaluvadi MR, Nyagode BA, Kinloch RD, et al. TLR4-dependent and -independent regulation of hepatic cytochrome P450 in mice with chemically induced inflammatory bowel disease. Biochem Pharmacol 2009; 77: 464–71PubMedCrossRef

36.

Ashino T, Arima Y, Shioda S, et al. Effect of interleukin-6 neutralization on cyp3a11 and metallothionein-1/2 expressions in arthritic mouse liver. Eur J Pharmacol 2007; 558: 199–207PubMedCrossRef

37.

Burger D, Dayer JM, Palmer G, et al. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 2006; 20: 879–96PubMedCrossRef

38.

Hoffman HM. Rilonacept for the treatment of cryopyrin associated periodic syndromes (CAPS). Expert Opin Biol Ther 2009; 9(4): 519–31PubMedCrossRef

39.

Kuemmerle-Deschner J, Hachulla E, Cartwright R, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011; 70: 2095–102PubMedCrossRef

Title: Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody
Authors: Abhijit Chakraborty, PhD
Stacey Tannenbaum
Christiane Rordorf
Philip J. Lowe
David Floch
Hermann Gram
Sandip Roy
Publication date: 01-06-2012
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 6/2012
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.2165/11599820-000000000-00000

At a glance: The STEP trials

Springer Medicine

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal Pregnancy

Clinical Pharmacokinetics and Therapeutic Efficacy of Esmolol

Vinflunine Oral Pharmacokinetics and Absolute Bioavailability of Soft and Hard Gelatin Capsules

Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease